"Peter Molloy graduated from the University of Melbourne as a microbiologist and biochemist and then worked for 18 years in the pharmaceutical industry. At the Australian pharmaceutical company, Faulding, he managed several Faulding subsidiaries, before joining Pharmacia (now Pfizer) as Managing Director of its Australia and NZ operations, where he managed four pharmaceutical marketing divisions including the oncology business. Promoted to Vice President of Strategic Marketing, he was then responsible for Pharmacia’s marketing strategy and portfolio across 22 countries throughout Asia-Pacific and Latin America.Subsequently, he served as CEO of three biotechnology companies – Biota Holding Ltd, SLIL Biomedical Corp and Florigene Ltd – where he managed numerous R&D programs, raised substantial equity funding and executed four pharmaceutical partnerships. During his tenure as CEO of the ASX-listed company, Biota Holdings Ltd, the company’s market value grew from approximately $30m to nearly $300m in three and a half years. Previously, as CEO of the US company, SLIL Biomedical Corp, he managed R&D and licensing for the company’s oncology drug development program. During his career, he has managed seven biotechnology or pharmaceutical businesses, launched 23 pharmaceutical products, and executed 40 international licensing or distribution deals. He holds a BSc from the University of Melbourne and an MBA from the University of Adelaide. He is also a Fellow of the Australian Institute of Company Directors and has served on several Australian and US boards, both as managing director and non-executive director. "Peter Molloy graduated from the University of Melbourne as a microbiologist and biochemist and then worked for 18 years in the pharmaceutical industry. At the Australian pharmaceutical company, Faulding, he managed several Faulding subsidiaries, before joining Pharmacia (now Pfizer) as Managing Director of its Australia and NZ operations, where he managed four pharmaceutical marketing divisions including the oncology business. Promoted to Vice President of Strategic Marketing, he was then responsible for Pharmacia’s marketing strategy and portfolio across 22 countries throughout Asia-Pacific and Latin America.Subsequently, he served as CEO of three biotechnology companies – Biota Holding Ltd, SLIL Biomedical Corp and Florigene Ltd – where he managed numerous R&D programs, raised substantial equity funding and executed four pharmaceutical partnerships. During his tenure as CEO of the ASX-listed company, Biota Holdings Ltd, the company’s market value grew from approximately $30m to nearly $300m in three and a half years. Previously, as CEO of the US company, SLIL Biomedical Corp, he managed R&D and licensing for the company’s oncology drug development program. During his career, he has managed seven biotechnology or pharmaceutical businesses, launched 23 pharmaceutical products, and executed 40 international licensing or distribution deals. He holds a BSc from the University of Melbourne and an MBA from the University of Adelaide. He is also a Fellow of the Australian Institute of Company Directors and has served on several Australian and US boards, both as managing director and non-executive director.

Pharmaceutical industry